Sirio Pharma Co., Ltd. (300791.SZ) Bundle
Who's buying Sirio Pharma and why does it matter to investors? With heavy hitters reshaping the shareholder base-Vanguard Group's 15% stake (a 5% increase in Q3 2023) alongside BlackRock's 12%-and Fidelity and State Street adding to their positions, these institutions now account for a combined 30% stake among the top four backers, signaling concentrated interest in the mid-cap firm; beneath this headline, Sirio's fundamentals show a CNY 4.21 billion revenue base in 2024 with a CNY 7.04 billion market capitalization (Dec 2025), while institutional ownership sits at 17.63% and insiders hold 20.76%-and strategic moves like the 2023 acquisition of Best Formulations LLC, plus a reported 7.7% net profit margin in 2024, help explain analyst forecasts of a potential 20-25% price upside over the next 12 months, making this a must-read profile for anyone tracking shareholder shifts and growth catalysts at 300791.SZ.
Sirio Pharma Co., Ltd. (300791.SZ) - Who Invests in Sirio Pharma Co., Ltd. (300791.SZ) and Why?
Sirio Pharma attracts a mix of large passive and active institutional investors drawn by solid margins, growth initiatives and targeted M&A that expand its product and geographic reach. Key motivations cited by investors include predictable cash flow from established product lines, a 7.7% net profit margin on CNY 4.21 billion revenue in 2024, and strategic tuck‑ins such as the 2023 acquisition of Best Formulations LLC that accelerate access to new formulations and overseas markets.- Scale and stewardship: Large asset managers value Sirio's market position and governance track record, enabling meaningful index exposure and active-engagement opportunities.
- Margin stability: A 7.7% net margin on CNY 4.21 billion revenue in 2024 signals resilient profitability in a competitive pharma environment.
- Growth via M&A: The 2023 Best Formulations LLC purchase provides product diversification and bolsters R&D and manufacturing capabilities, a clear growth lever for investors.
- Regulatory and market access upside: Investors anticipate further commercialization gains and international expansion from recent strategic moves.
| Investor | Current Stake | Change (noted period) | Interpretation |
|---|---|---|---|
| Vanguard Group | 15% | +5% (Q3 2023) | Increased conviction - shift toward larger passive/index exposure and selective active adds |
| BlackRock | 12% | 0 (maintained past two quarters) | Stable core holding consistent with long-term allocation strategy |
| Fidelity Investments | 5% | +2% (Q3 2023) | Active accumulation reflecting positive performance outlook |
| State Street Corporation | 8% | +3% (recent) | Growing interest-likely a mix of passive flows and tactical purchases |
- Financial snapshot (2024): Revenue CNY 4.21 billion; net profit margin 7.7% - figures that underpin institutional confidence.
- Strategic catalysts: Acquisition of Best Formulations LLC (2023) is highlighted by investors as a material inorganic growth driver and margin enhancer.
- Investor mix: Combination of large passive managers (Vanguard, BlackRock, State Street) and active asset managers (Fidelity) provides both stability and potential for additional upside through active engagement.
Sirio Pharma Co., Ltd. (300791.SZ) Institutional Ownership and Major Shareholders of Sirio Pharma Co., Ltd. (300791.SZ)
Sirio Pharma's shareholder structure as of December 2025 shows meaningful insider confidence alongside modest institutional participation, positioning the company as a mid-cap with room to attract further institutional capital.- Institutional ownership: 17.63% (Dec 2025)
- Insider (management and related parties) ownership: 20.76% (Dec 2025)
- Market capitalization: CNY 7.04 billion (Dec 2025)
| Shareholder | Type | Stake (%) | Notes |
|---|---|---|---|
| Vanguard Group | Institutional | 15.00 | Largest institutional holder |
| State Street Corporation | Institutional | 8.00 | Second-largest institutional holder |
| Insiders (management & related parties) | Insider | 20.76 | Significant executive/board alignment |
| Other institutional investors (each <5%) | Institutional | - | Remaining institutional holdings are dispersed among multiple investors |
| Free float / retail | Public | Approx. 55.21 | Residual free float after stated holdings |
- Distribution note: after Vanguard's 15% and State Street's 8%, no other single institutional investor holds ≥5%.
- Relative positioning: with 17.63% institutional ownership, Sirio Pharma's institutional penetration is relatively low vs. many consumer staples peers, indicating potential upside for institutional inflows if scale or liquidity improves.
Sirio Pharma Co., Ltd. (300791.SZ) Key Investors and Their Impact on Sirio Pharma Co., Ltd. (300791.SZ)
Sirio Pharma's shareholder base is anchored by large institutional investors whose stakes and recent moves materially affect governance, liquidity and market perception. The four highlighted investors now collectively control a substantial portion of free float, signaling strong institutional conviction.- Vanguard Group - 15% stake (up 5 percentage points in Q3 2023; prior ~10%)
- BlackRock - 12% stake (stable)
- Fidelity Investments - 5% stake (added 2 percentage points in Q3 2023; prior ~3%)
- State Street Corporation - 8% stake (up 3 percentage points in Q3 2023; prior ~5%)
| Investor | Current Stake (%) | Q3 2023 Change (ppt) | Previous Stake (%) | Immediate Impact |
|---|---|---|---|---|
| Vanguard Group | 15 | +5 | 10 | Provides large capital base, strategic guidance, potential board influence |
| BlackRock | 12 | 0 | 12 | Stability and signaling effect to other institutional investors |
| Fidelity Investments | 5 | +2 | 3 | Growing conviction in growth trajectory; potential for follow-on buys |
| State Street Corporation | 8 | +3 | 5 | Positive reassessment of prospects; adds index/ETF buying pressure |
| Total (key investors) | 40 | +10 | 30 | Concentrated institutional ownership - higher liquidity, valuation support |
- Improve stock liquidity through larger, consistent block trades and ETFs
- Raise valuation multiples by reducing perceived investment risk
- Facilitate partnerships and licensing deals due to enhanced credibility
- Increase scrutiny and governance expectations from major asset managers
Sirio Pharma Co., Ltd. (300791.SZ) Market Impact and Investor Sentiment
Institutional accumulation in Sirio Pharma has materially shifted market dynamics and sentiment. As of late 2025, four major asset managers-Vanguard Group, BlackRock, Fidelity Investments, and State Street Corporation-hold a combined 30% stake, signaling strong institutional confidence and providing a stabilizing base for the stock.
- Combined institutional stake (Vanguard, BlackRock, Fidelity, State Street): 30% (late 2025)
- Analyst consensus 12-month upside target: +20-25%
- 2024 revenue: CNY 4.21 billion; net profit margin: 7.7%
- Strategic M&A: Acquisition of Best Formulations LLC (2023)
- Institutional ownership vs. peers: relatively low, indicating room for inflows
| Metric | Value / Detail |
|---|---|
| Major institutional ownership (combined) | 30% (Vanguard, BlackRock, Fidelity, State Street) - late 2025 |
| 2024 Revenue | CNY 4.21 billion |
| 2024 Net Profit Margin | 7.7% |
| Notable M&A | Best Formulations LLC (acquired 2023) |
| Analyst 12‑month price target range | Projected +20% to +25% |
| Relative institutional ownership vs. industry peers | Lower than many pharmaceutical peers - implies potential for increased institutional allocation |
Drivers of recent sentiment and market impact include:
- Liquidity and share support from top-tier global asset managers that reduce volatility and signal validation to other investors.
- Financial resilience: a CNY 4.21 billion revenue base with a 7.7% net margin in 2024 that underpins valuation arguments.
- M&A-led growth: the 2023 Best Formulations LLC acquisition broadens the product pipeline and U.S./international access, enhancing strategic upside.
- Analyst momentum: consensus forecasts of 20-25% upside create a technical and narrative catalyst for additional inflows.
- Institutional runway: lower institutional penetration relative to peers represents an addressable opportunity set for large managers seeking healthcare exposure in China.
Market reaction to these factors has been generally positive but measured; sentiment is best characterized as cautiously optimistic, with investors watching execution on integration, margin expansion, and continued institutional participation. Additional context on ownership, mission and history is available here: Sirio Pharma Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money
Sirio Pharma Co., Ltd. (300791.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.